Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.
Journal
Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
10
2018
accepted:
09
12
2018
entrez:
7
2
2019
pubmed:
7
2
2019
medline:
7
2
2019
Statut:
epublish
Résumé
Notch signaling is frequently activated in ovarian cancer (OC) and contributes to the proliferation and survival of cultured OC cells as well as to tumor formation and angiogenesis in xenograft models. Several studies demonstrate that Notch3 expression renders cancer cells more resistant to carboplatin, contributing to chemoresistance and poor survival of OC-bearing patients. This suggests that Notch3 can represent both a biomarker and a target for therapeutic interventions in OC patients. Although it is still unclear how chemoresistance arises, different lines of evidence support a critical role of cancer stem cells (CSCs), suggesting that CSC targeting by innovative therapeutic approaches might represent a promising tool to efficiently reduce OC recurrence. To date, CSC-directed therapies in OC tumors are mainly targeted to the inhibition of CSC-related signaling pathways, including Notch. As it is increasingly evident the involvement of Notch signaling, and in particular of Notch3, in regulating stem-like cell maintenance and expansion in several tumors, here we provide an overview of the current knowledge of Notch3 role in CSC-mediated OC chemoresistance, finally exploring the potential design of innovative Notch3 inhibition-based therapies for OC treatment, aimed at eradicating tumor through the suppression of CSCs.
Identifiants
pubmed: 30723507
doi: 10.1155/2019/6264931
pmc: PMC6339748
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6264931Références
N Engl J Med. 2004 Dec 9;351(24):2519-29
pubmed: 15590954
Cancer Res. 2005 Apr 15;65(8):3025-9
pubmed: 15833827
Nature. 2005 Jun 16;435(7044):959-63
pubmed: 15959515
Nat Med. 2006 Mar;12(3):296-300
pubmed: 16520777
Cancer Res. 2006 Jun 15;66(12):6312-8
pubmed: 16778208
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9
pubmed: 16849428
Stem Cells. 2006 Nov;24(11):2437-47
pubmed: 16888285
Nature. 2007 Apr 12;446(7137):749-57
pubmed: 17429392
FASEB J. 2007 Dec;21(14):3777-85
pubmed: 17625071
Cell Cycle. 2007 Nov 15;6(22):2730-4
pubmed: 18032925
Cancer Res. 2008 Jun 1;68(11):4311-20
pubmed: 18519691
Oncogene. 2009 Jan 15;28(2):209-18
pubmed: 18836486
Cancer Lett. 2009 Jun 28;279(1):8-12
pubmed: 19022563
Nat Biotechnol. 2009 Jan;27(1):44-6
pubmed: 19131997
Int Immunol. 2009 Jun;21(6):727-43
pubmed: 19461123
Cell. 2009 Aug 21;138(4):645-659
pubmed: 19682730
Stem Cells. 2010 Jan;28(1):5-16
pubmed: 19904829
Oncogene. 2010 Mar 11;29(10):1463-74
pubmed: 19966856
Oncogene. 2010 May 6;29(18):2672-80
pubmed: 20190812
Br J Cancer. 2010 Apr 13;102(8):1276-83
pubmed: 20354527
Cancer Sci. 2010 Sep;101(9):1977-83
pubmed: 20624166
Am J Pathol. 2010 Sep;177(3):1087-94
pubmed: 20671266
Cancer Res. 2010 Dec 1;70(23):9937-48
pubmed: 21118965
Nature. 2011 Jan 20;469(7330):314-22
pubmed: 21248838
Cancer Res. 2011 Feb 1;71(3):634-9
pubmed: 21266356
Gynecol Oncol. 2011 May 1;121(2):390-4
pubmed: 21272926
Cancer Res. 2011 Jun 1;71(11):3991-4001
pubmed: 21498635
Nat Rev Cancer. 2011 May;11(5):338-51
pubmed: 21508972
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Mol Med Rep. 2012 Feb;5(2):552-8
pubmed: 22038279
Clin Cancer Res. 2012 Feb 1;18(3):869-81
pubmed: 22142828
Cancer Res. 2012 Feb 1;72(3):576-80
pubmed: 22298594
Am J Clin Pathol. 2012 Oct;138(4):535-44
pubmed: 23010708
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2939-48
pubmed: 23019585
J Ovarian Res. 2012 Oct 18;5(1):30
pubmed: 23078816
Clin Cancer Res. 2013 Apr 15;19(8):1972-80
pubmed: 23444212
Pharmacol Ther. 2013 Aug;139(2):95-110
pubmed: 23458608
J Ovarian Res. 2013 Mar 22;6(1):18
pubmed: 23522567
PLoS One. 2013 Aug 13;8(8):e68187
pubmed: 23967051
Pharmacol Ther. 2014 Feb;141(2):140-9
pubmed: 24076266
Curr Mol Med. 2014 Jan;14(1):34-44
pubmed: 24236458
EMBO Mol Med. 2014 Jan;6(1):99-119
pubmed: 24357640
EMBO Rep. 2014 Mar;15(3):244-53
pubmed: 24531722
J Cancer. 2014 Mar 16;5(5):301-10
pubmed: 24723972
Nat Rev Drug Discov. 2014 Jul;13(7):497-512
pubmed: 24981363
Cancer Res. 2014 Oct 1;74(19):5572-84
pubmed: 25125655
Oncotarget. 2014 Aug 30;5(16):7027-39
pubmed: 25216521
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Mol Carcinog. 2016 Jul;55(7):1196-209
pubmed: 26207830
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Oncogene. 2016 Sep 8;35(36):4741-51
pubmed: 26876201
Cancer Cell. 2016 Mar 14;29(3):367-378
pubmed: 26977885
Int J Oncol. 2016 Jun;48(6):2349-58
pubmed: 27035162
Oncotarget. 2016 Aug 23;7(34):55771-55788
pubmed: 27304054
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S8-S19
pubmed: 27611937
Biochim Biophys Acta. 2016 Dec;1866(2):276-289
pubmed: 27751894
Cancer Lett. 2017 Feb 1;386:168-178
pubmed: 27887917
Mol Cancer. 2017 Feb 1;16(1):28
pubmed: 28148265
Sci Transl Med. 2017 Mar 8;9(380):
pubmed: 28275151
Mol Cancer. 2017 Mar 20;16(1):64
pubmed: 28320418
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Stem Cells Int. 2017;2017:5263974
pubmed: 28819364
J Cancer. 2017 Sep 20;8(16):3331-3342
pubmed: 29158806
Cancer Res. 2018 Feb 15;78(4):938-949
pubmed: 29259010
Stem Cells. 2018 May;36(5):633-640
pubmed: 29352734
Expert Opin Ther Targets. 2018 Apr;22(4):331-342
pubmed: 29527929
J Neurosci. 2018 Mar 28;38(13):3157-3159
pubmed: 29593070
Development. 2018 May 15;145(10):
pubmed: 29695612
Oncogenesis. 2018 May 25;7(5):42
pubmed: 29795369